Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LAB

Standard BioTools Inc

May 07 • 11:40AM ET

2.39

Dollar change -0.09
Percentage change -3.43	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VTI VXF VHT IWC DFAC ITOT FHLC AVUS DFUS

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	3.54%	Shs Outstand	383.05M	Perf Week	-3.43%
Market Cap	917.40M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	1.89%	Shs Float	369.48M	Perf Month	-16.84%
Income	-74.66M	PEG	-	EPS next Q	-0.11	Inst Own	54.66%	Short Float	3.05%	Perf Quarter	0.21%
Sales	106.34M	P/S	8.63	EPS this Y	62.14%	Inst Trans	-1.55%	Short Ratio	4.96	Perf Half Y	14.59%
Book/sh	-1.85	P/B	-	EPS next Y	48.37%	ROA	-20.93%	Short Interest	11.28M	Perf Year	47.84%
Cash/sh	0.30	P/C	7.99	EPS next 5Y	-	ROE	-37.99%	52W Range	1.54 - 3.16	Perf YTD	8.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.72%	ROI	-37.79%	52W High	-24.21%	Beta	1.67
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	-0.06%	Gross Margin	47.24%	52W Low	55.52%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	1.45	EPS Y/Y TTM	61.39%	Oper. Margin	-60.36%	RSI (14)	38.03	Volatility	4.47% 5.53%
Employees	539	Debt/Eq	0.60	Sales Y/Y TTM	8.57%	Profit Margin	-70.21%	Recom	1.00	Target Price	3.58
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	5.49%	Payout	-	Rel Volume	0.50	Prev Close	2.48
Sales Surprise	13.20%	EPS Surprise	-4.17%	Sales Q/Q	4.32%	Earnings	May 08 AMC	Avg Volume	2.27M	Price	2.39
SMA20	-7.80%	SMA50	-8.22%	SMA200	-1.32%	Trades		Volume	417,291	Change	-3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
08:12AM	Loading…
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
08:30AM	Loading…
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)
05:54AM	Loading…
Nov-09-23 05:54AM	Q3 2023 Somalogic Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
Nov-08-23 12:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:52AM	Q3 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:23PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:30AM	Standard BioTools to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-25-23 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -10.50%
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-05-23 02:42PM	Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm (PR Newswire)
Oct-04-23 06:49PM	Why SomaLogic Stock Dived by 10% on Wednesday (Motley Fool) -22.22%
08:52AM	Standard BioTools to Combine with SomaLogic in $1 Billion Merger (Bloomberg)
08:00AM	Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools (GlobeNewswire)
Aug-09-23 09:06AM	Q2 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) +7.56%
Aug-08-23 05:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-23 04:05PM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 07:33AM	Strong week for Standard BioTools (NASDAQ:LAB) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
Jun-14-23 07:30AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-13-23 01:30PM	With 45% ownership, Standard BioTools Inc. (NASDAQ:LAB) has piqued the interest of institutional investors (Simply Wall St.)
May-25-23 04:05PM	Standard BioTools to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:11AM	With Standard BioTools Up 29%, Insider Buyers Count Their Returns \ (Simply Wall St.)
06:05AM	Jeffrey Black Spends US$194k On Standard BioTools Stock \ (Simply Wall St.)
May-18-23 07:30AM	Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System (GlobeNewswire) +12.05%
May-15-23 07:30AM	Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
May-10-23 02:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.85%
06:16AM	Q1 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 06:11PM	Standard BioTools: Q1 Earnings Snapshot (AP Finance)
04:05PM	Standard BioTools Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 04:30PM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-20-23 05:03PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-23 10:42AM	Standard BioTools Inc.'s (NASDAQ:LAB) Low P/S No Reason For Excitement (Simply Wall St.)
Apr-17-23 08:30AM	Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology (GlobeNewswire)
Mar-22-23 08:30AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-23 08:30AM	Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors (GlobeNewswire)
Mar-14-23 08:30AM	Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire) +11.05%
Mar-01-23 04:05PM	Standard BioTools to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-17-23 06:43PM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-15-23 06:01PM	How a Peninsula biotech tools company looks to corral 'one-trick ponies' (American City Business Journals)
Feb-14-23 04:05PM	Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook (GlobeNewswire)
Feb-03-23 05:30AM	The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable (Simply Wall St.)
Jan-31-23 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-09-23 08:30AM	Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update (GlobeNewswire) +6.45%
Jan-03-23 08:30AM	Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer (GlobeNewswire) +11.11%
Dec-24-22 08:01AM	Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year (Simply Wall St.)
Nov-28-22 08:30AM	Standard BioTools Authorizes up to $20 Million of Share Repurchases (GlobeNewswire) +10.00%
Nov-22-22 09:20AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-22 05:02AM	Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) (Simply Wall St.) +26.42%
Nov-08-22 04:05PM	Standard BioTools Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems (GlobeNewswire) -9.82%
Oct-25-22 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (GlobeNewswire) +14.95%
Oct-13-22 08:30AM	Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China (GlobeNewswire)
Oct-06-22 08:30AM	Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform (GlobeNewswire)
Aug-25-22 04:05PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-22 10:38AM	Is Standard BioTools (NASDAQ:LAB) Using Debt In A Risky Way? (Simply Wall St.)
Aug-08-22 04:02PM	Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update (GlobeNewswire) +7.94%
Jul-25-22 04:30PM	Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results (GlobeNewswire) -6.80%
Jul-04-22 11:56AM	Shareholders in Standard BioTools (NASDAQ:LAB) have lost 86%, as stock drops 12% this past week (Simply Wall St.)
May-05-22 04:02PM	Standard BioTools Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-22-22 04:02PM	Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results (GlobeNewswire)
Apr-11-22 08:30AM	Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging (GlobeNewswire)
Apr-05-22 07:30AM	Labrador Gold Intersects 6.07 g/t Au Over 19 Metres at the Big Vein Target, Kingsway Property (GlobeNewswire) -7.02%
Mar-29-22 08:00AM	Labrador Gold Extends High-Grade Gold Mineralization to 250m Southwest of Big Vein Discovery (GlobeNewswire) +10.61%

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Egholm Michael	President & CEO	Apr 04 '24	Option Exercise	0.00	196,512	0	422,030	Apr 05 06:59 PM
Kim Hanjoon Alex	Chief Operating Officer	Apr 04 '24	Option Exercise	0.00	70,183	0	140,366	Apr 05 06:58 PM
Casdin Partners Master Fund, L	Director	Mar 05 '24	Buy	2.62	1,403	3,669	11,497,928	Mar 06 07:20 PM
Casdin Partners Master Fund, L	Director	Mar 04 '24	Buy	2.57	250,000	642,500	11,496,525	Mar 06 07:20 PM
Casdin Eli	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:00 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 19 '23	Buy	2.29	42,492	97,213	85,984	May 22 06:49 PM
Casdin Eli	Director	May 18 '23	Buy	2.16	150,000	323,865	400,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 18 '23	Buy	2.16	150,000	323,865	400,000	May 19 09:00 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 18 '23	Buy	2.22	43,492	96,365	43,492	May 22 06:49 PM
Casdin Eli	Director	May 17 '23	Buy	1.89	250,000	471,550	250,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 17 '23	Buy	1.89	250,000	471,550	250,000	May 19 09:00 PM

Open in Screener

BLFS

Biolife Solutions Inc

May 07 • 11:40AM ET

18.42

Dollar change +0.27
Percentage change 1.46	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

BLFS Biolife Solutions Inc daily Stock Chart

Held by: IJR VTI IWM VXF IWO IJT IJS SCHA VIOO VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.52	Insider Own	4.71%	Shs Outstand	45.17M	Perf Week	4.99%
Market Cap	834.20M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-4.11%	Shs Float	43.17M	Perf Month	6.38%
Income	-66.43M	PEG	-	EPS next Q	-0.32	Inst Own	100.79%	Short Float	7.18%	Perf Quarter	1.80%
Sales	143.27M	P/S	5.82	EPS this Y	42.31%	Inst Trans	5.04%	Short Ratio	7.89	Perf Half Y	61.25%
Book/sh	7.48	P/B	2.46	EPS next Y	47.56%	ROA	-15.40%	Short Interest	3.10M	Perf Year	-4.78%
Cash/sh	1.14	P/C	16.13	EPS next 5Y	10.00%	ROE	-18.93%	52W Range	8.92 - 24.50	Perf YTD	13.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.51%	ROI	-17.94%	52W High	-24.84%	Beta	1.76
Dividend TTM	-	Quick Ratio	1.83	Sales past 5Y	57.29%	Gross Margin	29.02%	52W Low	106.44%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	2.86	EPS Y/Y TTM	53.47%	Oper. Margin	-40.16%	RSI (14)	60.24	Volatility	4.82% 5.81%
Employees	414	Debt/Eq	0.13	Sales Y/Y TTM	-11.43%	Profit Margin	-46.37%	Recom	1.25	Target Price	22.86
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	74.02%	Payout	-	Rel Volume	0.55	Prev Close	18.15
Sales Surprise	-2.00%	EPS Surprise	12.20%	Sales Q/Q	-26.04%	Earnings	May 09 AMC	Avg Volume	392.72K	Price	18.42
SMA20	8.27%	SMA50	6.06%	SMA200	21.26%	Trades		Volume	79,308	Change	1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-04-24	Initiated	Jefferies	Buy	$22
Jul-11-23	Initiated	Craig Hallum	Buy	$29
Apr-25-22	Upgrade	Oppenheimer	Perform → Outperform	$28
Oct-19-21	Initiated	B. Riley Securities	Buy	$61
Oct-15-21	Resumed	Cowen	Outperform	$64
May-14-21	Downgrade	The Benchmark Company	Buy → Hold
Mar-23-21	Upgrade	The Benchmark Company	Hold → Buy	$54
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$40
Sep-22-20	Downgrade	Oppenheimer	Outperform → Perform
Sep-18-20	Initiated	Cowen	Outperform	$33
Aug-11-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-08-20	Reiterated	Maxim Group	Buy	$18 → $26
Feb-24-20	Initiated	Lake Street	Buy	$25
Feb-19-20	Initiated	The Benchmark Company	Buy	$24
Feb-06-20	Resumed	B. Riley FBR	Buy	$27
Jan-08-20	Initiated	Stephens	Overweight	$23
Nov-21-19	Initiated	Oppenheimer	Outperform	$22
Jul-22-19	Initiated	H.C. Wainwright	Buy	$23
Nov-10-17	Reiterated	Maxim Group	Buy	$7 → $8
Sep-19-17	Reiterated	Maxim Group	Buy	$6 → $7

Show Previous Ratings

May-02-24 10:01AM	BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-30-24 04:12PM	BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 (PR Newswire)
Apr-18-24 11:00AM	Insider Sell: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ... (GuruFocus.com)
08:05AM	BioLife Solutions Announces the Divestiture of its Stirling Freezer Business (PR Newswire)
Mar-27-24 04:37PM	Corporate Insiders Are Selling These 10 Small-Cap Stocks (Insider Monkey)
02:15AM	Loading…
Mar-14-24 02:15AM	Director Amy Duross Sells 11,200 Shares of BioLife Solutions Inc (BLFS) (GuruFocus.com)
Mar-13-24 01:50AM	Insider Sell: Chief Marketing Officer Todd Berard Sells 7,508 Shares of BioLife Solutions Inc (BLFS) (GuruFocus.com) +5.77%
Mar-04-24 08:03AM	BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences (PR Newswire)
Mar-02-24 08:16AM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:02AM	Q4 2023 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents) +6.33%
Feb-29-24 04:03PM	BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-20-24 08:03AM	BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024 (PR Newswire)
Jan-08-24 08:15AM	BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue (PR Newswire) +10.16%
Nov-16-23 02:54AM	BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles (Insider Monkey)
Nov-10-23 02:33PM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:04PM	Loading…
Nov-09-23 04:04PM	BioLife Solutions Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-02-23 04:03PM	BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023 (PR Newswire) +8.02%
12:27AM	Former CEO Michael Rice Sells 72,603 Shares of BioLife Solutions Inc (GuruFocus.com)
Oct-19-23 05:04PM	BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023 (PR Newswire)
Oct-09-23 04:24AM	New Strong Sell Stocks for October 9th (Zacks)
Sep-13-23 07:47AM	New Strong Sell Stocks for September 13th (Zacks)
Aug-11-23 04:06PM	Why Shares of BioLife Solutions Plummeted This Week (Motley Fool)
06:05AM	Some BioLife Solutions, Inc. (NASDAQ:BLFS) Analysts Just Made A Major Cut To Next Year's Estimates (Simply Wall St.)
Aug-09-23 01:38PM	Why Shares of BioLife Solutions Are Slumping on Wednesday (Motley Fool) -28.71%
Aug-08-23 06:30PM	BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business (PR Newswire)
Jul-27-23 04:03PM	BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023 (PR Newswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-21-23 08:00PM	BLFS: What does Argus have to say about BLFS? (Argus Research)
Jun-14-23 08:03AM	BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities (PR Newswire)
08:03AM	Loading…
Jun-06-23 08:03AM	BioLife Solutions Launches the IntelliRate i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer (PR Newswire)
May-12-23 07:45AM	We Think BioLife Solutions (NASDAQ:BLFS) Can Easily Afford To Drive Business Growth (Simply Wall St.)
May-11-23 07:34AM	Q1 2023 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents)
May-10-23 05:35PM	BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports First Quarter 2023 Financial Results (PR Newswire)
May-02-23 04:03PM	BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023 (PR Newswire) -5.03%
Apr-26-23 08:00PM	BLFS: Lowering target price to $14.00 (Argus Research)
Mar-20-23 10:46PM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 08:39AM	Q4 2022 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents) +7.71%
Mar-16-23 04:03PM	BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results (PR Newswire) -6.98%
Mar-13-23 09:40AM	Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? (Zacks) +6.51%
Mar-10-23 03:38PM	BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank (PR Newswire) -13.33%
Mar-09-23 04:03PM	BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023 (PR Newswire)
Mar-01-23 08:03AM	BioLife Solutions Launches Ultraguard -70°C Phase Change Material (PCM) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage (PR Newswire)
Feb-17-23 09:40AM	Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-26-23 08:00AM	iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors (GlobeNewswire)
Jan-17-23 08:04AM	BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences (PR Newswire) +5.99%
Jan-10-23 08:05AM	BioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work For (PR Newswire)
Jan-09-23 08:05AM	BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance (PR Newswire) +9.00%
Jan-06-23 07:31AM	Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued? (Simply Wall St.)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research)
Dec-19-22 08:03AM	BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023 (PR Newswire)
Dec-18-22 04:43PM	Should You Invest in BioLife Solutions (BLFS)? (Insider Monkey)
Dec-10-22 07:12AM	Investors push BioLife Solutions (NASDAQ:BLFS) 11% lower this week, company's increasing losses might be to blame (Simply Wall St.)
Nov-21-22 08:05AM	BioLife Solutions Expands Intellectual Property Estate (PR Newswire)
Nov-17-22 08:05AM	BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report (PR Newswire) -6.31%
Nov-11-22 05:27AM	BioLife Solutions Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 06:05PM	BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -14.99%
04:05PM	BioLife Solutions Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:52AM	Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 49% Undervaluation? (Simply Wall St.)
Oct-11-22 10:10AM	CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market (PR Newswire)
Oct-03-22 08:03AM	BioLife Solutions Announces COO to Retire and Join Board of Directors (PR Newswire)
Aug-25-22 08:03AM	BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors (PR Newswire)
Aug-09-22 06:35PM	BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:07PM	BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance (PR Newswire)
Aug-02-22 04:05PM	BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022 (PR Newswire)
Jul-18-22 06:20AM	Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load? (Simply Wall St.)
Jun-09-22 08:05AM	BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services (PR Newswire)
Jun-02-22 12:34PM	Investing in BioLife Solutions (NASDAQ:BLFS) five years ago would have delivered you a 496% gain (Simply Wall St.) +5.99%
May-09-22 05:45PM	BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.80%
04:03PM	BioLife Solutions Reports First Quarter 2022 Financial Results (PR Newswire)
May-05-22 05:15PM	Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.72%
May-02-22 07:28PM	BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022 (PR Newswire)
07:47AM	New Strong Sell Stocks for May 2nd (Zacks)
Apr-26-22 11:18AM	3 Oversold Stocks That Could Be Ready for a Comeback (TipRanks)
Apr-07-22 04:45PM	BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP (PR Newswire)
Mar-31-22 06:44AM	New Strong Sell Stocks for March 31st (Zacks)
Mar-18-22 05:43PM	BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing (PR Newswire) +7.33%
Mar-17-22 08:05AM	BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K (PR Newswire) +6.65%
Mar-15-22 08:05AM	BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market (PR Newswire)
Mar-01-22 08:05AM	BioLife Solutions to Attend and Present at Upcoming Investor Conferences (PR Newswire)
Feb-28-22 06:15PM	BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Feb-21-22 08:03AM	BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022 (PR Newswire)
Feb-11-22 11:40AM	PETQ or BLFS: Which Is the Better Value Stock Right Now? (Zacks)
Feb-02-22 05:16AM	Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt? (Simply Wall St.)
Feb-01-22 05:38PM	Horan Capital Advisors, LLC. Buys BorgWarner Inc, Cincinnati Bancorp Inc, Schwab Emerging ... (GuruFocus.com)
Jan-27-22 05:38PM	Peoples Bank Buys BioLife Solutions Inc, iShares 0-5 Year TIPS Bond ETF, SPDR Portfolio Short ... (GuruFocus.com) -6.11%
Jan-10-22 08:00AM	BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020 (PR Newswire)
Jan-04-22 08:06AM	BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing (PR Newswire)
Dec-16-21 10:15AM	Biolife Solutions Inc (BLFS) CEO Michael Rice Sold $1.1 million of Shares (GuruFocus.com) -5.06%
08:03AM	UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines (PR Newswire)
Dec-10-21 10:15AM	Biolife Solutions Inc (BLFS) CEO Michael Rice Sold $821,403 of Shares (GuruFocus.com)
Dec-09-21 09:15AM	Biolife Solutions Inc (BLFS) EVP & Chief Scientific Officer Aby J. ... (GuruFocus.com)
Nov-19-21 11:50AM	COO Of Biolife Solutions Makes $1.1M Sale (Benzinga)
Nov-18-21 10:31AM	Notable Biolife Solutions Insider Trades $1.0M In Company Stock (Benzinga)
Nov-17-21 01:08PM	BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500 (PR Newswire)
Nov-15-21 08:05AM	BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies (PR Newswire) +5.55%
Nov-11-21 07:30PM	BioLife Solutions Inc (BLFS) Q3 2021 Earnings Call Transcript (Motley Fool)
04:05PM	BioLife Solutions Announces Third Quarter 2021 Financial Results (PR Newswire)

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aebersold Sarah	Chief Human Resources Officer	Apr 22 '24	Sale	16.50	410	6,765	65,085	Apr 23 07:15 PM
Wichterman Troy	Chief Financial Officer	Apr 18 '24	Sale	15.31	956	14,636	126,658	Apr 23 07:14 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Apr 18 '24	Sale	15.31	584	8,941	319,098	Apr 23 07:14 PM
Foster Karen A.	Chief Quality and Operations	Apr 18 '24	Sale	15.31	481	7,364	158,664	Apr 23 07:14 PM
Aebersold Sarah	Chief Human Resources Officer	Apr 18 '24	Sale	15.31	348	5,328	65,495	Apr 23 07:15 PM
Berard Todd	Chief Marketing Officer	Apr 18 '24	Sale	15.31	332	5,083	129,312	Apr 23 07:14 PM
Berard Todd	Chief Marketing Officer	Apr 15 '24	Sale	15.67	10,000	156,700	129,644	Apr 18 08:18 AM
Aebersold Sarah	Chief Human Resources Officer	Apr 01 '24	Sale	17.65	4,000	70,600	65,843	Apr 03 05:17 PM
Berard Todd	Chief Marketing Officer	Mar 27 '24	Sale	17.99	515	9,265	139,644	Mar 29 05:39 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 27 '24	Sale	17.99	454	8,167	319,682	Mar 29 05:40 PM
Foster Karen A.	Chief Quality and Operations	Mar 27 '24	Sale	17.99	395	7,106	159,145	Mar 29 05:39 PM
Wichterman Troy	Chief Financial Officer	Mar 21 '24	Sale	17.83	520	9,272	127,614	Mar 25 05:03 PM
DuRoss Amy	Director	Mar 13 '24	Sale	17.00	5,065	86,105	29,443	Mar 13 06:37 PM
Wichterman Troy	Chief Financial Officer	Mar 12 '24	Sale	16.60	7,249	120,333	128,134	Mar 12 09:43 PM
DE GREEF RODERICK	President and CEO	Mar 12 '24	Sale	16.60	7,249	120,333	461,854	Mar 12 09:43 PM
Berard Todd	Chief Marketing Officer	Mar 12 '24	Sale	16.60	7,107	117,976	140,159	Mar 12 09:44 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 12 '24	Sale	16.60	6,521	108,249	320,136	Mar 12 09:44 PM
DuRoss Amy	Director	Mar 12 '24	Sale	16.86	6,135	103,436	34,508	Mar 13 06:37 PM
Foster Karen A.	Chief Quality and Operations	Mar 12 '24	Sale	16.60	5,177	85,938	159,540	Mar 12 09:43 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 12 '24	Sale	16.60	4,361	72,393	69,843	Mar 12 09:42 PM
Phillips Geraint	SVP, Global Operations	Mar 12 '24	Sale	16.60	3,598	59,727	65,998	Mar 12 09:44 PM
Berard Todd	Chief Marketing Officer	Mar 11 '24	Sale	17.42	401	6,985	147,266	Mar 12 09:44 PM
Wichterman Troy	Chief Financial Officer	Mar 11 '24	Sale	17.42	361	6,289	135,383	Mar 12 09:43 PM
Foster Karen A.	Chief Quality and Operations	Mar 11 '24	Sale	17.42	319	5,557	164,717	Mar 12 09:43 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 11 '24	Sale	17.42	313	5,452	326,657	Mar 12 09:44 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 11 '24	Sale	17.42	269	4,686	74,204	Mar 12 09:42 PM
Phillips Geraint	SVP, Global Operations	Mar 11 '24	Sale	17.42	206	3,589	69,596	Mar 12 09:44 PM
Phillips Geraint	SVP, Global Operations	Feb 21 '24	Sale	17.35	131	2,273	58,120	Feb 23 05:51 PM
Berard Todd	Chief Marketing Officer	Feb 21 '24	Sale	17.35	111	1,926	115,688	Feb 23 05:51 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Feb 21 '24	Sale	17.35	101	1,752	275,214	Feb 23 05:51 PM
Wichterman Troy	Chief Financial Officer	Feb 21 '24	Sale	17.35	97	1,683	64,823	Feb 23 05:51 PM
Foster Karen A.	Chief Quality and Operations	Feb 21 '24	Sale	17.35	87	1,509	123,940	Feb 23 05:50 PM
Aebersold Sarah	Chief Human Resources Officer	Feb 21 '24	Sale	17.35	58	1,006	41,806	Feb 23 05:52 PM
Aebersold Sarah	Chief Human Resources Officer	Jan 23 '24	Sale	17.11	336	5,749	41,864	Jan 25 05:10 PM
DE GREEF RODERICK	President and CEO	Jan 19 '24	Sale	16.76	2,642	44,280	439,897	Jan 23 05:29 PM
Wichterman Troy	Chief Financial Officer	Jan 19 '24	Sale	16.76	2,419	40,542	64,920	Jan 23 05:29 PM
Phillips Geraint	SVP, Global Operations	Jan 19 '24	Sale	16.76	1,776	29,766	58,251	Jan 23 05:30 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jan 19 '24	Sale	16.76	1,450	24,302	275,315	Jan 23 05:30 PM
Berard Todd	Chief Marketing Officer	Jan 19 '24	Sale	16.76	1,232	20,648	115,799	Jan 23 05:29 PM
Foster Karen A.	Chief Quality and Operations	Jan 19 '24	Sale	16.76	1,198	20,078	124,027	Jan 23 05:30 PM
Aebersold Sarah	Chief Human Resources Officer	Jan 19 '24	Sale	16.76	862	14,447	42,200	Jan 23 05:29 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jan 02 '24	Sale	16.75	697	11,675	276,765	Jan 04 05:03 PM
Foster Karen A.	Chief Quality and Operations	Jan 02 '24	Sale	16.75	601	10,067	125,225	Jan 04 05:04 PM
Berard Todd	Chief Marketing Officer	Jan 02 '24	Sale	16.75	491	8,224	117,031	Jan 04 05:04 PM
Wichterman Troy	Chief Financial Officer	Dec 22 '23	Sale	16.79	314	5,272	67,339	Dec 28 04:46 PM
Wichterman Troy	Chief Financial Officer	Dec 01 '23	Sale	12.37	666	8,238	67,112	Dec 04 07:14 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Dec 01 '23	Sale	12.37	591	7,311	275,961	Dec 04 07:15 PM
Foster Karen A.	Chief Quality Officer	Dec 01 '23	Sale	12.37	466	5,764	125,340	Dec 04 07:15 PM
Aebersold Sarah	Chief Human Resources Officer	Dec 01 '23	Sale	12.37	394	4,874	43,062	Dec 04 07:15 PM
Berard Todd	Chief Marketing Officer	Dec 01 '23	Sale	12.37	394	4,874	117,522	Dec 04 07:14 PM
Phillips Geraint	SVP, Global Operations	Dec 01 '23	Sale	12.37	303	3,748	59,587	Dec 04 07:14 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 13 '23	Sale	10.77	132	1,422	275,726	Nov 15 10:41 AM
Foster Karen A.	Chief Quality Officer	Nov 13 '23	Sale	10.77	114	1,228	125,539	Nov 15 10:41 AM
Phillips Geraint	SVP, Global Operations	Nov 13 '23	Sale	10.66	111	1,183	59,656	Nov 15 10:41 AM
Berard Todd	Chief Marketing Officer	Nov 13 '23	Sale	10.77	98	1,055	117,916	Nov 15 10:41 AM
Wichterman Troy	Chief Financial Officer	Nov 13 '23	Sale	10.66	97	1,034	67,480	Nov 15 10:40 AM
Aebersold Sarah	Chief Human Resources Officer	Nov 13 '23	Sale	10.77	76	819	43,456	Nov 15 10:41 AM
Rice Michael	Former CEO and Director	Oct 30 '23	Sale	9.13	72,603	662,865	347,085	Nov 01 05:30 PM
Casdin Partners Master Fund, L	10% Owner	Oct 19 '23	Buy	11.19	927,165	10,374,976	8,557,165	Oct 23 05:42 PM
Rice Michael	Chief Executive Officer	Sep 28 '23	Sale	14.16	831	11,767	418,635	Oct 02 05:07 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 28 '23	Sale	14.16	659	9,331	273,121	Oct 02 05:04 PM
Foster Karen A.	Chief Quality Officer	Sep 28 '23	Sale	14.16	568	8,043	124,767	Oct 02 05:08 PM
Berard Todd	Chief Marketing Officer	Sep 28 '23	Sale	14.16	464	6,570	118,014	Oct 02 04:56 PM
Wichterman Troy	Chief Financial Officer	Sep 21 '23	Sale	12.70	539	6,845	66,300	Sep 25 04:57 PM
Rice Michael	Chief Executive Officer	Aug 25 '23	Sale	10.99	1,729	19,002	416,906	Aug 29 05:53 PM
Wichterman Troy	Chief Financial Officer	Aug 25 '23	Sale	10.99	585	6,429	65,933	Aug 29 05:51 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Aug 25 '23	Sale	10.99	519	5,704	271,220	Aug 29 05:53 PM
Foster Karen A.	Chief Quality Officer	Aug 25 '23	Sale	10.99	410	4,506	124,342	Aug 29 05:52 PM
Aebersold Sarah	Chief Human Resources Officer	Aug 25 '23	Sale	10.99	347	3,814	43,532	Aug 29 05:48 PM
Schulz Marcus	Chief Revenue Officer	Aug 25 '23	Sale	10.99	347	3,814	42,097	Aug 29 05:54 PM
Berard Todd	Chief Marketing Officer	Aug 25 '23	Sale	10.99	347	3,814	118,478	Aug 29 05:50 PM
Phillips Geraint	SVP, Global Operations	Aug 25 '23	Sale	10.99	179	1,967	58,045	Aug 29 05:49 PM
Rice Michael	Chief Executive Officer	Aug 14 '23	Sale	12.38	277	3,429	418,635	Aug 16 04:49 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Aug 14 '23	Sale	12.38	180	2,228	271,739	Aug 16 04:48 PM
Foster Karen A.	Chief Quality Officer	Aug 14 '23	Sale	12.38	156	1,931	124,752	Aug 16 04:46 PM
Berard Todd	Chief Marketing Officer	Aug 14 '23	Sale	12.38	134	1,659	118,825	Aug 16 04:48 PM
Phillips Geraint	SVP, Global Operations	Aug 14 '23	Sale	12.57	109	1,370	58,224	Aug 16 04:47 PM
Schulz Marcus	Chief Revenue Officer	Aug 14 '23	Sale	12.38	108	1,337	42,444	Aug 16 04:49 PM
Aebersold Sarah	Chief Human Resources Officer	Aug 14 '23	Sale	12.38	104	1,288	43,879	Aug 16 04:46 PM
Wichterman Troy	Chief Financial Officer	Aug 14 '23	Sale	12.57	94	1,182	66,518	Aug 16 04:47 PM
Casdin Partners Master Fund, L	10% Owner	Aug 09 '23	Buy	13.20	58,465	771,744	7,630,000	Aug 11 05:01 PM
Schulz Marcus	Chief Revenue Officer	Jul 24 '23	Sale	19.50	679	13,240	42,552	Jul 26 06:09 PM
Aebersold Sarah	Chief Human Resources Officer	Jul 24 '23	Sale	19.50	462	9,009	43,983	Jul 26 06:08 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jul 20 '23	Option Exercise	2.06	10,000	20,600	281,919	Jul 24 04:35 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jul 20 '23	Sale	20.07	10,000	200,700	271,919	Jul 24 04:35 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jul 19 '23	Option Exercise	2.06	10,000	20,600	281,919	Jul 24 04:35 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jul 19 '23	Sale	20.46	10,000	204,600	271,919	Jul 24 04:35 PM
Schulz Marcus	Chief Revenue Officer	Jul 11 '23	Sale	22.79	331	7,543	43,231	Jul 13 05:10 PM
Rice Michael	Chief Executive Officer	Jun 27 '23	Sale	22.91	877	20,092	418,912	Jun 29 04:40 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 27 '23	Sale	22.91	695	15,922	271,919	Jun 29 04:38 PM
Foster Karen A.	Chief Quality Officer	Jun 27 '23	Sale	22.91	590	13,517	124,908	Jun 29 04:37 PM
Berard Todd	Chief Marketing Officer	Jun 27 '23	Sale	22.91	489	11,203	118,959	Jun 29 04:35 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 22 '23	Option Exercise	2.06	10,000	20,600	282,614	Jun 23 04:58 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 22 '23	Sale	23.32	10,000	233,200	272,614	Jun 23 04:58 PM
Wichterman Troy	Chief Financial Officer	Jun 22 '23	Sale	23.41	541	12,665	66,612	Jun 26 04:36 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 21 '23	Option Exercise	2.06	10,000	20,600	282,614	Jun 23 04:58 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 21 '23	Sale	22.97	10,000	229,700	272,614	Jun 23 04:58 PM
Rice Michael	CEO	May 31 '23	Sale	23.21	1,679	38,970	419,789	Jun 02 08:00 PM
Wichterman Troy	Chief Financial Officer	May 31 '23	Sale	23.21	560	12,998	67,153	Jun 02 08:01 PM
Mathew Aby J.	EVP & Chief Scientific Officer	May 31 '23	Sale	23.21	504	11,698	272,614	Jun 02 08:02 PM

Open in Screener

MXCT

MaxCyte Inc

May 07 • 11:40AM ET

3.83

Dollar change -0.09
Percentage change -2.17	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO VHT DFAC IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.37	Insider Own	12.19%	Shs Outstand	103.96M	Perf Week	5.37%
Market Cap	398.30M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-1.40%	Shs Float	91.44M	Perf Month	-7.61%
Income	-37.92M	PEG	-	EPS next Q	-0.12	Inst Own	72.21%	Short Float	3.60%	Perf Quarter	-22.57%
Sales	41.29M	P/S	9.65	EPS this Y	-33.27%	Inst Trans	0.19%	Short Ratio	5.94	Perf Half Y	11.84%
Book/sh	2.23	P/B	1.71	EPS next Y	16.34%	ROA	-13.67%	Short Interest	3.29M	Perf Year	-19.64%
Cash/sh	1.62	P/C	2.37	EPS next 5Y	-	ROE	-15.60%	52W Range	2.45 - 5.55	Perf YTD	-18.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.20%	ROI	-15.16%	52W High	-31.02%	Beta	-
Dividend TTM	-	Quick Ratio	9.97	Sales past 5Y	20.83%	Gross Margin	78.86%	52W Low	56.12%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	10.65	EPS Y/Y TTM	-58.43%	Oper. Margin	-116.74%	RSI (14)	44.59	Volatility	5.49% 4.22%
Employees	143	Debt/Eq	0.08	Sales Y/Y TTM	-6.71%	Profit Margin	-91.84%	Recom	1.25	Target Price	8.45
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-8.07%	Payout	-	Rel Volume	0.26	Prev Close	3.91
Sales Surprise	16.53%	EPS Surprise	26.79%	Sales Q/Q	26.10%	Earnings	May 07 AMC	Avg Volume	553.33K	Price	3.83
SMA20	-1.28%	SMA50	-7.22%	SMA200	-7.25%	Trades		Volume	53,228	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Loading…
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire)
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
11:05AM	Loading…
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
04:54AM	Loading…
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)
Jan-03-23 04:05PM	MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs (PR Newswire) -6.23%
Dec-21-22 09:35AM	MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-19-22 12:55PM	7 Hot Stocks to Book Profits In Before 2023 (InvestorPlace)
Dec-16-22 06:42AM	MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-08-22 12:00PM	MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-05-22 02:00AM	MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases (GlobeNewswire) -10.69%
Nov-19-22 03:18AM	Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m (Simply Wall St.)
Nov-09-22 06:35PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.36%
05:35PM	MaxCyte Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-02-22 08:05AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-22 07:29PM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-20-22 10:16AM	MaxCyte (LON:MXCT) shareholders have earned a 65% CAGR over the last three years (Simply Wall St.)
Oct-18-22 11:38AM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-12-22 08:00AM	MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Sep-28-22 12:39PM	MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders (Benzinga) +7.57%
08:05AM	MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program (GlobeNewswire)
Sep-21-22 09:32AM	Montgomery County biotech MaxCyte unveils new HQ to expand headcount, manufacturing (American City Business Journals)
08:23AM	MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last? (Zacks)
08:05AM	MaxCyte Debuts New State-of-the-Art Headquarters in Marylands I-270 Biotech Corridor (GlobeNewswire)
Sep-13-22 12:30PM	Is it a Good Time to Dispose Your MaxCyte (MXCT) Shares? (Insider Monkey)
Sep-07-22 04:05PM	MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
01:29AM	RGAIA Investment: MacCyte (MXCT) is Uniquely Well Positioned to Benefit (Insider Monkey)
Aug-25-22 11:00AM	RGA Investment Advisors Considers MaxCyte (MXCT)s Business Model To Be High-Quality (Insider Monkey)
Aug-22-22 02:59AM	With 69% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns (Simply Wall St.) -5.87%
Aug-11-22 07:00AM	MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-10-22 05:25PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of MXCT.OQ earnings conference call or presentation 10-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results (PR Newswire)
Jul-15-22 08:00AM	MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022 (GlobeNewswire)
Jul-12-22 08:00AM	MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs (GlobeNewswire)
Jun-23-22 03:50AM	We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth (Simply Wall St.) +11.51%
May-13-22 04:30PM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:45AM	MaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 years (Simply Wall St.)
May-10-22 05:00AM	MaxCyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript (Motley Fool)
May-09-22 04:05PM	MaxCyte Reports First Quarter Financial Results (PR Newswire)
May-03-22 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.34%
Apr-20-22 04:05PM	MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022 (GlobeNewswire)
Apr-15-22 09:00AM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-12-22 04:05PM	MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue (GlobeNewswire)
Mar-22-22 11:30PM	MaxCyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript (Motley Fool)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year Financial Results (PR Newswire)
Mar-15-22 03:56AM	Is MaxCyte, Inc. (LON:MXCT) Popular Amongst Institutions? (Simply Wall St.)
Mar-09-22 04:15PM	MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer (GlobeNewswire)
Feb-24-22 08:00AM	MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022 (GlobeNewswire)
Feb-14-22 08:00AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-11-22 05:00PM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-22 02:00AM	MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs (GlobeNewswire)
Jan-24-22 02:30AM	MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results (GlobeNewswire) +5.31%
Jan-14-22 06:53AM	Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnston John Joseph	Director	Mar 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Mar 26 '24	Sale	4.41	5,000	22,025	120,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Jan 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Jan 26 '24	Sale	5.12	5,000	25,585	120,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Option Exercise	2.14	5,000	10,710	125,583	Dec 28 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Sale	4.53	5,000	22,650	120,583	Dec 28 04:30 PM
Doerfler Douglas	President and CEO	Dec 05 '23	Option Exercise	0.04	99,442	3,978	432,639	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 05 '23	Sale	5.17	99,442	514,115	333,197	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 04 '23	Option Exercise	0.04	25,008	1,000	358,205	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 04 '23	Sale	5.01	25,008	125,290	333,197	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 01 '23	Option Exercise	0.04	20,200	808	353,397	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Dec 01 '23	Sale	5.00	20,200	101,000	333,197	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Nov 29 '23	Option Exercise	0.04	5,350	214	338,547	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Nov 29 '23	Sale	5.00	5,350	26,750	333,197	Dec 01 05:14 PM
Johnston John Joseph	Director	Nov 27 '23	Option Exercise	2.14	5,000	10,710	125,583	Nov 29 04:36 PM
Johnston John Joseph	Director	Nov 27 '23	Sale	4.59	5,000	22,950	120,583	Nov 29 04:36 PM
Johnston John Joseph	Director	Nov 14 '23	Option Exercise	1.71	10,000	17,053	130,583	Nov 16 04:48 PM
Johnston John Joseph	Director	Nov 14 '23	Sale	3.71	10,000	37,100	120,583	Nov 16 04:48 PM
Johnston John Joseph	Director	Aug 30 '23	Option Exercise	1.64	2,841	4,662	123,424	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 30 '23	Sale	3.70	2,841	10,512	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 29 '23	Option Exercise	1.64	2,059	3,379	122,642	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 29 '23	Sale	3.70	2,059	7,618	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 28 '23	Option Exercise	1.64	100	164	120,683	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 28 '23	Sale	3.70	100	370	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Jul 26 '23	Option Exercise	1.64	5,000	8,205	125,583	Jul 28 04:30 PM
Johnston John Joseph	Director	Jul 26 '23	Sale	4.75	5,000	23,750	120,583	Jul 28 04:30 PM
Doerfler Douglas	President and CEO	Jul 12 '23	Option Exercise	0.04	16,757	670	349,954	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 12 '23	Sale	5.02	16,757	84,120	333,197	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 11 '23	Option Exercise	0.04	12,798	512	345,995	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 11 '23	Sale	5.04	12,798	64,502	333,197	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 10 '23	Option Exercise	0.04	445	18	333,642	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 10 '23	Sale	5.01	445	2,229	333,197	Jul 12 06:06 PM
Johnston John Joseph	Director	Jun 27 '23	Option Exercise	1.64	7,471	12,260	128,054	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 27 '23	Sale	4.39	7,471	32,798	120,583	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 26 '23	Option Exercise	1.05	7,529	7,870	128,112	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 26 '23	Sale	4.49	7,529	33,805	120,583	Jun 28 05:05 PM
Doerfler Douglas	President and CEO	Jun 14 '23	Option Exercise	0.04	28,883	1,155	362,080	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 14 '23	Sale	5.04	28,883	145,570	333,197	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 13 '23	Option Exercise	0.04	14,968	599	348,165	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 13 '23	Sale	5.03	14,968	75,289	333,197	Jun 15 04:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LAB

Standard BioTools Inc

BLFS

Biolife Solutions Inc

MXCT

MaxCyte Inc

Upgrade your FINVIZ experience